SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing significant downward pressure following disappointing quarterly delivery figures and intensifying competition in the EV sector. Investors are actively debating the company's long-term prospects as capital increasingly shifts toward anticipation of the upcoming SpaceX IPO.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending following the announcement of subscription price increases across all U.S. tiers, a move that analysts view as a strategic leverage of pricing power to fuel content investment. While the community is split between bullish sentiment over potential revenue gains and frustration regarding rising costs, traders are closely watching the stock for a breakout above the key 100 level as volume and institutional interest pick up.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is rallying following a significant earnings beat and positive 2026 guidance, which has spurred optimism regarding its pivot to commercial storage and AI data center energy demand. While the community remains divided on whether this is a durable trend reversal or a temporary relief rally for a stock that has struggled significantly over the past two years, traders are actively debating the impact of upcoming debt obligations and ongoing regulatory headwinds in the solar sector.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is surging as investors react to a stronger-than-expected bookings forecast for the second half of the year, signaling that its AI wafer-level burn-in technology is finally reaching mass adoption. The community is buzzing over potential new contract wins with major hyperscalers, with many long-term holders actively debating the company's valuation as it integrates into the critical AI infrastructure supply chain.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is currently experiencing intense volatility and downward pressure following a recent reverse split, leaving the community deeply divided between frustrated long-term shareholders and short-sellers profiting from the decline. Investors are actively debating the company's long-term viability, citing concerns over management's silence on financial guidance and a lack of major sports network partnerships, while some traders continue to look for potential short-squeeze opportunities.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Investors are actively discussing a potential relisting and the company's recent strategic moves, including the acquisition of Blue Bottle operations, as they weigh the stock's long-term global ecosystem potential against current OTC volatility. The community remains focused on valuation gaps, signs of institutional accumulation, and the end of intense local price wars that previously pressured margins.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing significant trading activity driven by persistent market speculation regarding a potential acquisition by major tech and space players like Amazon or SpaceX. The community is actively debating the strategic value of the company's spectrum assets and the impact of Apple's existing partnership, with many long-term shareholders dismissing lower buyout rumors as undervaluation.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is surging following the FDA approval of VYKAT XR, the first treatment for hyperphagia in patients with Prader-Willi syndrome. Investors are actively discussing the stock's significant valuation shift from a clinical-stage biotech to a commercial-stage company, while monitoring the potential for a long-term buyout in a sector seeing heavy consolidation.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant community buzz as investors look ahead to upcoming earnings, with high anticipation for fiscal 2027 revenue guidance and updates on the QNX royalty backlog. Shareholders are debating the company's valuation against its strategic position in the software-defined vehicle market, with many focused on the potential for long-term growth driven by key partnerships and the foundational role of QNX technology in automotive architectures.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently trending as investors debate whether recent production challengesspecifically laser dicing issues at their Malaysia facilityrepresent a major setback or a solvable engineering hurdle on the path to high-volume commercialization. The community is heavily split between long-term bulls highlighting institutional interest and potential partnerships, and skeptical traders who are focused on the stock's recent decline toward all-time lows and a perceived lack of immediate, large-scale purchase orders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics Inc. stock ended Wednesday deep in the red but rose 1.3% in extended trading after the company announced encouraging data from a cancer drug trial.The company reported final survival data from a Phase 2a trial of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">CAN-2409</a> in advanced lung cancer patients who did not respond well to immune checkpoint inhibitors (ICI).&nbsp;The median overall survival (mOS) was 24.5 months for those receiving two courses of CAN-2409, significantly higher than the 9.8-11.8 months seen in similar patients receiving standard chemotherapy.The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.&nbsp;Patients with non-squamous non-small cell lung cancer (NSCLC) showed the most potent response, with a mOS of 25.4 months in this group. Biomarker analysis indicated a stronger immune response in these patients than in those with squamous NSCLC.The treatment also appeared to induce a systemic immune response, as 69% of patients with multiple tumors saw reductions in untreated lesions.&nbsp;CAN-2409 maintained a favorable safety profile throughout the extended follow-up period, the company added.The news sent message volume about Candel on Stocktwits soaring by over 120%, with sentiment climbing further within the ‘neutral’ territory (53/100) from a day ago.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/CADL_sentiment_and_message_volume_as_of_Macrh_26_png_1c49d17460.webp" alt="CADL sentiment and message volume as of Macrh 26.png" width="1318" height="302"><figcaption>CADL sentiment and message volume as of Macrh 26. | source: Stocktwits</figcaption></figure>One optimistic user said CAN-2409 "is worth billions," adding that Candel also had successful phase-3 trials in prostate cancer and a successful phase-2 in pancreatic cancer.<stembedurl>https://stocktwits.com/strategicmind/message/609387743</stembedurl>Another compared Candel to small-cap biotech firms that were acquired by established pharma giants such as Gilead and Pfizer for tens of billions of dollars, saying the company “will join this GOAT rodeo in no time.”<stembedurl>https://stocktwits.com/chrundel/message/609386559</stembedurl>“I could see this becoming [the] standard of care for adenocarcinoma of the lung,” said another user based on the data.<stembedurl>https://stocktwits.com/Uromaster/message/609354605</stembedurl>Last month, Candel shared updated survival data from Phase 2a trials of CAN-2409 in pancreatic cancer.&nbsp;Meanwhile, Phase 1b survival data for CAN-3110 in recurrent high-grade glioma is expected in the fourth quarter of 2025, and the company plans to submit a Biologics License Application (BLA) for CAN-2409 in prostate cancer in Q4 2026.Candel stock is down about 12% this year but has gained more than 390% in the past 12 months.&nbsp;According to Koyfin, three out of four analysts covering Candel rate it ‘buy’ while one recommends a ‘strong buy.’For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration showing chimeric antigen receptor (CAR) T cells (blue and green) being used to treat non-small cell lung cancer (NSCLC). | Representative image: Getty Images

Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years. 

Equity

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years. 


Shares of Candel Therapeutics Inc. surged nearly 10% on Wednesday and extended gains in after-hours trading following a bullish call from Wall Street.Canaccord initiated coverage on the stock with a ‘Buy’ rating and a $20 price target, implying a 91% upside from the last close.&nbsp;The research firm expects continued clinical success for Candel’s lead asset, CAN-2409, in prostate, pancreatic, and non-small cell lung cancer.&nbsp;In testing so far, CAN-2409 has shown a significant increase in median overall survival. If this trend continues, it could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst.&nbsp;On Stocktwits, sentiment turned ‘extremely bullish’ on Wednesday as message volume jumped by 50% and new followers increased by 4%.&nbsp;<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CADL_sentiment_and_message_volume_Feb_19_d3c9416772.png" alt="CADL sentiment and message volume Feb 19.png" width="1316" height="316"><figcaption>CADL sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>Traders speculated that upcoming data could drive a major rally, with some predicting that strong results from the pancreatic study could push shares into the $30-$40 range.<stembedurl>https://stocktwits.com/Xanderzzzzzzz/message/604910450</stembedurl><stembedurl>https://stocktwits.com/drizz/message/604899234</stembedurl>Last week, BofA Securities also&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-surges-on-bofa-buy-call/chPzAKRRtG">initiated</a> coverage on Candel with a ‘Buy’ rating and a $15 price target, citing promising early data for CAN-2409 and CAN-3110 as key drivers of its bullish outlook.&nbsp;The research firm noted that CAN-2409’s early results in prostate cancer suggest a potential breakthrough, while CAN-3110 has shown signs of nearly doubling overall survival in patients with recurrent high-grade glioma.Candel has outlined several key milestones ahead.&nbsp;Updated overall survival data from Phase 2a trials of CAN-2409 in pancreatic and non-small cell lung cancer is expected in the first quarter of 2025.&nbsp;Phase 1b survival data for CAN-3110 in recurrent high-grade glioma is set for the fourth quarter of 2025, while a Biologics License Application (BLA) submission for CAN-2409 in prostate cancer is targeted for the fourth quarter of 2026.<a href="https://stocktwits.com/symbol/CADL">Candel stock</a> is up more than 22% this year. Short interest was 6.2% as of last week, down from 14.1% at the start of the year, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice

CAN-2409 could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst. 

Shares of Mullen Automotive Inc. (MULN) plunged nearly 28% on Wednesday, hitting new record lows after quarterly results showed widening losses that further dented retail investor confidence.The struggling EV maker reported first-quarter (Q1) revenue of $2.9 million, stating that it produced more revenue this quarter than in the past two fiscal years combined.&nbsp;However, net losses ballooned by over 46%, with a net loss of $114.9 million attributable to common shareholders after preferred dividends.While adjusted losses per share narrowed to $661.33 from $91,940.42 a year earlier, the company noted that this figure accounted for retroactive reverse stock splits, including a 1:60 split that took <a href="https://stocktwits.com/news-articles/markets/equity/muln-stock-slides-on-reverse-split-plan/ch5icstRHs">effect</a> this week.&nbsp;Most losses were non-cash expenses totaling $91 million, making up 79% of the quarter's total loss.CEO David Michery tried to highlight a positive milestone, saying that $4.4 million worth of invoices were issued and $6 million in vehicle payments were received, marking Mullen's strongest quarter to date.&nbsp;The company's Bollinger segment completed the sale of 20 units, generating $2.8 million in revenue.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CVNA_sentiment_and_message_volume_Feb_19_d795e38b8c.png" alt="CVNA sentiment and message volume Feb 19.png" width="1318" height="324"><figcaption>CVNA sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment turned 'extremely bearish,' with message volume ticking up as traders weighed Mullen's financial strain.One user pointed to Mullen's crippling balance sheet, noting that the company already owed a lot of money to GEM Group from a lost arbitration case."This is an insolvent company," the user concluded.<stembedurl>https://stocktwits.com/KendallP/message/604814133</stembedurl>Another skeptical trader mocked potential buyers.<stembedurl>https://stocktwits.com/FourFingerFred/message/604807224</stembedurl>Mullen in December submitted a modified plan to the U.S. Department of Energy (DOE) seeking $55 million in matching funds to support U.S.-based battery and pack production.&nbsp;Additionally, the company has implemented cost-cutting measures, reducing headcount and personnel costs by $13 million annually.However, <a href="https://stocktwits.com/symbol/MULN">MULN stock</a> has lost over 99% of its value in the past year, reflecting a sharp decline in investor confidence amid legal hurdles, financial distress, and lackluster sales growth.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bear Market and falling chart - stock photo

Mullen's Stock Plumbs New Depths After Q1 Net Loss Balloons By 46%, Retail Traders Throw In The Towel

Most losses were non-cash expenses totaling $91 million, making up 79% of the quarter's total loss.

Mullen Automotive shares slid on Friday morning after plunging over 26% in the previous session, as&nbsp;investors responded negatively to the EV maker’s 1-for-60 reverse stock split&nbsp;announcement.&nbsp;The move aims to help Mullen regain compliance with Nasdaq’s $1 minimum bid price rule. The split will take effect on Feb. 18.On Stocktwits, Mullen’s sentiment meter shifted to ‘neutral’ from ‘bullish’ amid increased message volume.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MULN_sentiment_Feb_14_4cf83233f7.png" alt="MULN sentiment Feb 14.png" width="1318" height="324"><figcaption>MULN sentiment and message volume on Feb 14 as of 10:00 am ET | source: Stocktwits</figcaption></figure>Bearish posts pointed to reports of a legal setback: Mullen lost a lawsuit against GEM Group, which it had accused of unregistered securities dealing and market manipulation.&nbsp;<stembedurl>https://stocktwits.com/KendallP/message/604248065</stembedurl>A court&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://storage.courtlistener.com/recap/gov.uscourts.nysd.615724/gov.uscourts.nysd.615724.148.0.pdf">filing</a> confirmed the ruling against Mullen, ordering the company to pay over $26 million in damages plus interest within 90 days — a sum that bearish retail traders noted far exceeds the EV maker’s current market capitalization and annual revenue.Mullen only recently moved from pre-revenue development to commercial EV sales, reporting $400,000 in revenue for fiscal 2023 and about $1.1 million in fiscal 2024.&nbsp;However, its net loss for the twelve months ended Sept. 30, 2024, widened as non-cash impairment charges climbed to $119.2 million from $84.6 million the prior year.&nbsp;The company&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/01/24/3015112/0/en/Mullen-Reports-Improved-2024-Financial-Results.html">cited</a> ongoing funding challenges and a sharp decline in its market cap as key drivers of the charge.Cash and equivalents dropped to $10.3 million from $155.3 million a year earlier, while total debt stood just below $20 million.Still, some bullish traders speculated that Mullen’s upcoming quarterly earnings report could trigger a rebound, suggesting the reverse split was strategically timed ahead of the release.&nbsp;<stembedurl>https://stocktwits.com/DEDBEARS/message/604286050</stembedurl>The company has also seen some recent positive developments, including last month’s purchase of battery line equipment from Nikola for its Fullerton facility and new orders for its electric cargo vans from universities in Los Angeles and the San Francisco Bay Area.Earlier this year, Mullen reported better-than-expected road testing&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://electrek.co/2024/02/29/mullen-sees-better-than-expected-road-testing-results-from-energy-dense-solid-state-batteries/">results</a> for its solid-state batteries, showing promising gains in driving range.&nbsp;Founded in 2014, the company initially sought to revive a defunct EV model before pivoting to develop its vehicles.&nbsp;After a 2020 merger, Mullen <a href="https://stocktwits.com/news-articles/markets/equity/muln-stock-dips-after-cost-cut-plans/cJcQXH5REP">acquired</a> a majority stake in Bollinger Motors in 2023 and bought assets from bankrupt Electric Last Mile Solutions.Despite these efforts, investors remain cautious as Mullen navigates legal hurdles and financial strain.&nbsp;The stock has lost over 99% of its value in the past year, with the upcoming earnings report on Feb. 17 seen as a key test for the company’s growth narrative.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In 2022, Mullen spent $148 million acquiring Bollinger Motors and another $240 million on Electric Last Mile Solutions. Photo courtesy: Mullen

Mullen Automotive Stock In Reverse Gear On 1-For-60 Reverse Split Plan: Retail Sentiment Mixed

The stock has lost over 99% of its value in the past year, with the upcoming earnings report on Feb. 17 seen as a key test for the company’s growth narrative.

Shares of Candel Therapeutics Inc.&nbsp;(CADL)&nbsp;surged over 9% on Friday morning, reaching their highest level in nearly a month and setting the stage for their best weekly gain (+20%) since Dec. 20.BofA Securities initiated coverage of Candel with a 'Buy' rating and a $15 price target, according to The Fly, implying an upside of about 92% from the previous close.&nbsp;The brokerage highlighted promising early data for Candel's two lead drug candidates —&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/cadl-stock-soars-after-prostate-cancer-drug-trial-data/cJa3iD5R0a">CAN-2409</a> and CAN-3110 — as key drivers of its bullish outlook.The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments.&nbsp;BofA added that CAN-3110 has shown early indications of nearly doubling overall survival in patients with recurrent high-grade glioma.Last month, Candel provided a broad update on what to expect this year and beyond:<ul style="list-style-type:circle;"><li>Q1 2025: Updated overall survival data from Phase 2a clinical trials of CAN-2409 in pancreatic ductal adenocarcinoma and non-small cell lung cancer.</li><li>Q4 2025: Phase 1b overall survival data for CAN-3110 in patients with recurrent high-grade glioma.</li><li>Q4 2026: Biologics License Application (BLA) submission for CAN-2409 in prostate cancer.</li><li>Upcoming scientific conferences: Presentation of Phase 3 data for CAN-2409 in prostate cancer.</li></ul>Candel also disclosed that its cash and cash equivalents stood at approximately $103 million as of&nbsp;Dec. 31, 2024, which the company expects to fund its operations into the first quarter of 2027.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CADL_sentiment_and_message_volume_Feb_7_0ea124a0a6.png" alt="CADL sentiment and message volume Feb 7.png" width="1318" height="324"><figcaption>CADL sentiment and message volume Feb 7 as of 11 am ET | source: Stocktwits</figcaption></figure>Stocktwits sentiment on Candel flipped to ‘bullish’ (71/100) on Friday from a ‘bearish’ (42/100) reading last week, amid a spike in message volume.&nbsp;Retail traders cheered BofA's bullish rating, with one urging investors to stay long on the stock.<stembedurl>https://stocktwits.com/LongLTC/message/603284668</stembedurl>Adding to the optimism, a retail investor flagged a 13G&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/315066/000031506625000400/xslSCHEDULE_13G_X01/primary_doc.xml">filing</a> from Fidelity Investments on Friday, revealing that it now owns a 9.3% stake in Candel.<stembedurl>https://stocktwits.com/jzellner/message/603322436</stembedurl>Notably, according to Koyfin data, short interest in Candel stock dropped from 14.1% at the beginning of January to 6.9% by the end of the month.<a href="https://stocktwits.com/symbol/CADL">Candel shares</a> have skyrocketed 560% over the past 12 months — and with bullish sentiment building, some traders believe the rally is far from over.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Photo caption: BofA’s $15 price target implies an upside of about 92% from the previous close. | Image source: Getty Images

Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call

The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments.

HDG
ProShares Hedge Replication ETF

Feed

News

Sentiment

Fundamentals

Info

Latest HDG News

HDGProShares Hedge Replication ETF